Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

5.62
Delayed Data
As of 3:59pm ET
 -0.01 / -0.18%
Today’s Change
5.02
Today|||52-Week Range
11.18
-28.86%
Year-to-Date
Celgene's Revlimid Gains EU Nod for Mantle Cell Lymphoma
Jul 18 / Zacks.com - Paid Partner Content
Merrimack Pharmaceuticals Stock Sank Like a Stone in June
Jul 13 / MotleyFool.com - Paid Partner Content
ZIOPHARM (ZIOP) Stock Down on Patient Death in Phase I
Jul 18 / Zacks.com - Paid Partner Content
BioDelivery Sciences (BDSI) Catches Eye: Stock Rises 12%
Jul 13 / Zacks.com - Paid Partner Content
Gilead's HCV Drug Epclusa Gets Regulatory Nod in Canada
Jul 15 / Zacks.com - Paid Partner Content
CytRx (CYTR) Stock Falls on Unfavorable Aldoxorubicin Data
Jul 13 / Zacks.com - Paid Partner Content
Ultragenyx (RARE) Reports Positive Phase III rhGUS Data
Jul 15 / Zacks.com - Paid Partner Content
Comeback for Juno (JUNO) Stock? FDA Lifts Clinical Hold
Jul 13 / Zacks.com - Paid Partner Content
Bayer Expands Drug Discovery Collaboration with X-Chem
Jul 13 / Zacks.com - Paid Partner Content